Spear Bio

Spear Bio is a biotechnology startup that specializes in the detection of low abundance biomarkers, which are indicators of disease in the body. Their technology is particularly adept at identifying these biomarkers in the early stages of disease, with the ability to detect even single-digit counts of proteins per sample. This high level of precision is achieved through their proprietary 2-factor authentication detection technology.

The company's technology requires sub-microliter samples, which allows for minimally invasive sample collection. This makes it easier to conduct more tests from smaller samples, enabling broader scale research or screening, particularly in asymptomatic subjects.

Spear Bio's business model is based on providing this technology to labs, which can then use it to scale up testing for large groups of subjects. The technology is compatible with any non-proprietary qPCR instruments, meaning it can be easily automated on open liquid handling platforms. This flexibility allows labs to rapidly scale testing without needing to invest in proprietary instruments.

One of the company's key products is the NAB-Sure™ SARS CoV-2 Kit, which simplifies testing for SARS-CoV-2 neutralizing antibodies. The kit uses real-time PCR systems to produce both qualitative and quantitative measurements, combining high accuracy with unparalleled sensitivity.

In summary, Spear Bio operates in the biotechnology market, serving clients such as research labs and healthcare providers. Their business model is based on providing highly sensitive and precise biomarker detection technology, which can be easily integrated into existing lab setups. They generate revenue by selling their technology and testing kits to these clients.

Keywords: Biotechnology, Biomarker Detection, Minimally Invasive Sampling, qPCR Instruments, Automated Testing, SARS-CoV-2 Testing, Antibody Detection, Lab Technology, Precision Diagnostics, Healthcare Providers.